ClinVar Miner

Submissions for variant NM_000719.7(CACNA1C):c.1553G>A (p.Arg518His) (rs1057517711)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 3
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
GeneDx RCV000412828 SCV000490448 pathogenic not provided 2016-09-19 criteria provided, single submitter clinical testing The R518H pathogenic variant has previously been reported in one proband with LQTS (Boczek et al., 2015). In addition, this variant has been observed in other unrelated individuals referred for LQTS genetic testing at GeneDx, and was found to segregate with disease in at least one affected relative. The R518H variant was not observed in approximately 6,100 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, indicating it is not a common benign variant in these populations. Another pathogenic missense variant affecting the same residue (R518C) has been reported in the Human Gene Mutation Database in association with LQTS and hypertrophic cardiomyopathy (HCM) (Stenson et al., 2014). Although the R518H variant is a conservative amino acid substitution, which is not likely to impact secondary protein structure as these residues share similar properties, this substitution occurs at a position that is conserved across species, and in silico analysis predicts this variant is probably damaging to the protein structure/function. Furthermore, whole cell patch clamp studies revealed R518H results in loss of current density and inactivation in combination with increased window and late channel current (Boczek et al., 2015). In summary, R518H in the CACNA1C gene is interpreted as a pathogenic variant.
Agnes Ginges Centre for Molecular Cardiology,Centenary Institute RCV000584800 SCV000692528 likely pathogenic Familial hypertrophic cardiomyopathy 1 2017-04-19 criteria provided, single submitter research The CACNA1C Arg518His variant had been identified in a few probands with mixed phenotypes of Long QT, congenital heart defects and HCM (Boczek NJ, et al., 2015; Genedx, personal communication) and has been found to segregate in 2 families with varying phenotypes (Boczek NJ, et al., 2015). In vitro functional analysis using whole cell patch clamping confirmed the loss of current density and inactivation in combination with increased window and later voltage gated calcium channel current (Boczek NJ, et al., 2015), however this study may not necessarily reflect biological function and future studies will be useful to validate these findings. The variant is present a singleton event in the Exome Aggregation Consortium dataset (MAF= 0.00003230, We identified this variant in a patient diagnosed with HCM in their adoloscence, the patient had a known family history of disease and a prolonged QT was noted when the patient was in his 40s. The probands affected son also harbours this variant. He was diagnosed with HCM at 2 months. Computational tools SIFT, PolyPhen-2 and MutationTaster predict this variant to have deleterious effect. In summary, based on a few proband's reported with similar phenotypes, strong segregation data, rarity in general population databases, as well supportive in silico tools in combination with a functional study suggestive of an affect on protein function, we classify the CACNA1C Arg518His as "likely pathogenic".
Invitae RCV000631664 SCV000752747 likely pathogenic Long QT syndrome 2019-10-30 criteria provided, single submitter clinical testing This sequence change replaces arginine with histidine at codon 518 of the CACNA1C protein (p.Arg518His). The arginine residue is highly conserved and there is a small physicochemical difference between arginine and histidine. This variant is not present in population databases (ExAC no frequency). This variant has been reported in families affected with long QT syndrome or a complex phenotype of long QT syndrome and hypertrophic cardiomyopathy (PMID: 26253506, 30025578). ClinVar contains an entry for this variant (Variation ID: 372313). This variant has been reported to affect CACNA1C protein function (PMID: 26253506). This variant disrupts the p.Arg518 amino acid residue in CACNA1C. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 26253506, Invitae). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.